Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Lancet Diabetes Endocrinol. 2022 Nov 7;10(12):859–868. doi: 10.1016/S2213-8587(22)00277-7

Figure 1.

Figure 1.

Disposition of pivotal and supplemental patients with BBS and Alström syndrome. BBS, Bardet-Biedl syndrome. aSafety analysis set includes patients who received ≥1 dose of study drug (setmelanotide or placebo). bPlacebo-controlled analysis set includes randomized patients who received ≥1 dose of placebo or setmelanotide and had baseline data. cFull analysis set includes randomized patients who received ≥1 dose of setmelanotide and had baseline data.